Advertisement

Peroxisome Proliferation-Related Oxidative Stress and Hepato-Carcinogenesis

  • Janardan K. Reddy
  • M. Sambasiva Rao

Abstract

Investigation of the phenomenon of xenobiotic-induced peroxisome proliferation in liver parenchymal cells continues to provide fascinating details about the differential regulation of peroxisomal enzymes, their role in the production of intrahepatic oxidative stress and the possible relationship between sustained oxidative stress and the eventual development of hepatocellular carcinomas (1–3), Hepatic peroxisome proliferation was first noted nearly twenty years ago in the livers of rats treated with the hypolipidemic drug Clofibrate (4,5). Subsequently, several structurally diverse chemicals have been identified as hepatic peroxisome proliferators (1,2,6). Long-term feeding studies demonstrated the hepatocarcinogenicity of several of these agents (2,7–9), although they are not genotoxic in short-term tests (10–13). On the basis of these observations it was proposed that peroxisome proliferators form a novel class of chemical carcinogens (8), An understanding of the mechanism of induction of peroxisome proliferation and the metabolic events that accompany persistent increase in the number of these organelles is necessary to resolve the question whether these nongenotoxic hepatocarcinogenic peroxisome proliferators pose the same carcinogenic risk to humans as those that are genotoxic.

Keywords

Peroxisome Proliferators Clofibric Acid Liver Parenchymal Cell Hypolipidemic Drug Peroxisomal Fatty Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.K. Reddy J.R. Warren, M.K. Reddy, and N.D. Lalwani, Hepatic and renal effects of peroxisome proliferators: Biological implications. Ann.N.Y.Acad.Sci, 386, 81–110 (1982).PubMedCrossRefGoogle Scholar
  2. 2.
    J.K. Reddy and N.D. Lalwani, Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit.Rev.Toxicol. 12, 1–58 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    J.K. Reddy and M.S. Rao, Peroxisome proliferators and cancer: Mechanisms and implications. Trends Pharmacol.Sci. 7, 438–443 (1986).CrossRefGoogle Scholar
  4. 4.
    R. Hess, W. Staubli, and W. Riess, Nature of the hepatomegalic effect produced by ethylchlorophenoxyisobutyrate in the rat. Nature (London) 208, 856–858 (1985).CrossRefGoogle Scholar
  5. 5.
    D.J. Svoboda and D.L. Azamoff, Response of hepatic microbodies to a hypolipidemic agent, ethylchlorophenoxyisobutyrate (CPIB). J.Cell Biol. 30, 442–450 (1966).PubMedCrossRefGoogle Scholar
  6. 6.
    J.K. Reddy and T.P. Krishnakantha, Hepatic peroxisome proliferation: Induction by two novel compounds structurally unrelated to clofibrate. Science 190, 787–789 (1975).PubMedCrossRefGoogle Scholar
  7. 7.
    J.K. Reddy, M.S. Rao, and D.E. Moody, Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res. 36, 1211–1217 (1976).PubMedGoogle Scholar
  8. 8.
    J. K. Reddy, D.L. Azarnoff, and C.E. Hignite, Hypolipidemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (London) 283, 397–398 (1980).CrossRefGoogle Scholar
  9. 9.
    M.S. Rao, N.D. Lalwani, T.K. Watanabe, and J.K. Reddy, Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxy-anisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res. 44, 1072–1076 (1984).PubMedGoogle Scholar
  10. 10.
    J.R. Warren, V.F. Simmon, and J.K. Reddy, Properties gf hypolipidemic peroxisome proliferators in the lymphocyte:(H) thymidine and Salmonella mutagenesis assays. Cancer Res. 40, 36–41 (1980).PubMedGoogle Scholar
  11. 11.
    H.P. Dauert, J.K. Reddy, Y.S. Kennan, G.L. Sattler, V. Subbarao, and H.C. Pitot, Effect of hypolipidemic peroxisome proliferators on unscheduled DNA synthesis in cultured hepatocytes and on mutagenesis in Salmonella. Cancer Lett. 24, 147–156 (1984).CrossRefGoogle Scholar
  12. 12.
    A. Von Daniken, W.K. Lutz, R. Jaekl, and C. Schlatter, Investigation of the potential for binding of di(2-ethylhexyl)phthalate (DEHP) and di(2-ethylhexyl)adipate (DEHA) to liver DNA in vivo. Toxicol.Appl. Pharmacol. 73, 373–387 (1984).CrossRefGoogle Scholar
  13. 13.
    R.C. Gupta, S.K. Goel, K. Earley, B. Singh, and J.K. Reddy, P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro. Carcinogenesis 6, 933–936 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    W.M. Kluwe, J.K. Haseman, J.F. Douglas, and J.E. Huff, The carcinogenicity of dietary di(2-ethylhexyl)phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice. J.Toxicol.Environ.Health 10, 797–815 (1982).PubMedCrossRefGoogle Scholar
  15. 15.
    B.N. Ames, Identifying environmental chemicals causing mutations and cancer. Science 204, 587–593 (1979).PubMedCrossRefGoogle Scholar
  16. 16.
    P.B. Lazarow and C. de Duve, A fatty acyl-CoA oxidizing system in rat liver peroxisomes; Enhancement by Clofibrate, a hypolipidemic drug. Proc.Natl.Acad.Sci.U.S.A. 73, 2043–2046 (1976).PubMedCrossRefGoogle Scholar
  17. 17.
    N.E. Tolbert, Metabolic pathways in peroxisomes and glyoxysomes. Annu.Rev.Biochem. 50, 133–157 (1981).PubMedCrossRefGoogle Scholar
  18. 18.
    A.K. Hajra and J.E. Bishop, Glycerolipid biosynthesis in peroxisomes via the acyl dihydroxyacetone phosphate pathway. Ann.N.Y.Acad.Sci. 386, 170–182 (1982).PubMedCrossRefGoogle Scholar
  19. 19.
    J.K. Reddy, S.K. Goel, M.R. Nemali, J.J. Carrino, T.G. Laffler, M.K. Reddy, S.J. Sperbeck, T. Osumi, T. Hashimoto, N.D. Lalwani, and M.S. Rao, Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase β-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc.Natl.Acad.Sci.U.S.A. 83, 1747–1751 (1986).PubMedCrossRefGoogle Scholar
  20. 20.
    N.D. Lalwani, W.E. Fahl, and J.K. Reddy, Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds. Biochem.Biophys. Res.Commun. 116, 383–393 (1983).CrossRefGoogle Scholar
  21. 21.
    N.D. Lalwani, K. Alvares, M.K. Reddy, M.N. Reddy, I. Parikh, and J.K. Reddy, Peroxisome proliferator binding protein: Identification and partial characterization of nafenopin, clofibric acid and ciprofibrate binding proteins from rat liver. Proc.Natl.Acad.Sci.U.S.A. (in press).Google Scholar
  22. 22.
    M.S. Rao and J.K. Reddy, Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 8, 631–636 (1987).PubMedCrossRefGoogle Scholar
  23. 23.
    N.D. Lalwani, M.K. Reddy, S.A. Qureshi, and J.K. Reddy, Development of hepatocellular carcinomas and increased peroxisomal fatty acid 3-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis 7, 645–650 (1981).CrossRefGoogle Scholar
  24. 24.
    J.K. Reddy, M.K. Reddy, M.I. Usman, N.D. Lalwani, and M.S. Rao, Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl)adipate with a hypolipidemic drug. Environ.Health Perspect. 65, 317–327 (1986).PubMedGoogle Scholar
  25. 25.
    J.K. Reddy, N.D. Lalwani, M.K. Reddy, and S.A. Qureshi, Excessive accumulation autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res. 42, 259–266 (1982).PubMedGoogle Scholar
  26. 26.
    S.K. Goel, N.D. Lalwani, and J.K. Reddy, Peroxisome proliferation and lipid peroxidation in rat liver. Cancer Res. 46, 1324–1330 (1986).PubMedGoogle Scholar
  27. 27.
    B.G. Lake, S.L. Kozlen, J.G. Evans, T.J.B. Gray, P.J. Young, and S.D. Gangoli, Effect of prolonged administration of clofibric acid and di(2-ethylhexyl)phthalate on hepatic enzyme activities and lipid peroxidation in the rat. Toxicology 44, 213–228 (1987).PubMedCrossRefGoogle Scholar
  28. 28.
    B.M. Elliott, N.J.F. Dodd, and C.R. Elcombe, Increased hydroxyl radical production in liver peroxisomal fractions from rats treated with peroxisome proliferators. Carcinogenesis 7, 795–799 (1986).PubMedCrossRefGoogle Scholar
  29. 29.
    Y.C. Awasthi, S.V. Singh, S.K. Goel, and J.K. Reddy, Irreversible inhibition of hepatic glutathione s-transferase by ciprofibrate, a peroxisome proliferator. Biochem.Biophys.Res.Commun. 123, 1012–1018 (1984).PubMedCrossRefGoogle Scholar
  30. 30.
    K. Furukawa, S. Numoto, K. Furuya, N.T. Furukawa, and G.M. Williams, Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital. Cancer Res. 5011–5019 (1985).Google Scholar
  31. 31.
    P.A. Cerutti, Prooxidant states and tumor promotion. Science 228, 375–381 (1985).CrossRefGoogle Scholar
  32. 32.
    B.N. Ames, Dietary carcinogens and anticarcinogens. Science 221, 1256–1264 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Janardan K. Reddy
    • 1
  • M. Sambasiva Rao
    • 1
  1. 1.Department of PathologyNorthwestern University Medical SchoolChicagoUSA

Personalised recommendations